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The first pancreas transplant was performed in 19661 
and since then much has evolved. Refinements in surgi-
cal technique, immunosuppressive protocols and post-
operative care have led to progressively improved out-
comes. These results have encouraged many transplant 
centres to implement pancreas transplant programmes. 
Simultaneous pancreas-kidney transplantation (SPKT) 
has better medium- and long-term results than pan-
creas after kidney or pancreas transplantation alone. 
Based on this, since 2000 the American Diabetes Asso-
ciation has recommended SPKT as the pancreas trans-
plantation modality of choice for type-1 diabetes (DM1) 
patients with end-stage renal disease2,3. Pancreas after 
kidney transplantation is another option, especially for 
recipients having a living kidney donor. Pancreas trans-
plantation alone remains restricted for those with minor 
renal disease and labile diabetes, with history of fre-
quent ketoacidosis or hypoglycaemic coma episodes3. 
In recent years and mainly in the United States, some 
type-2 diabetes patients have also been considered 
for pancreas transplantation, following a very narrow 
selection process.
Successful SPKT frees the patient from dialysis, insulin 
and glucose monitoring, and from life-threatening hypo-
glycaemic episodes. Despite the initial increased 
morbidity and mortality, over time SPKT offers to select-
ed DM1 patients not only a better quality of life but also 
some improvements – or, at least, stabilization – in long-
term secondary diabetic complications compared to 
kidney transplantation alone.
This paper will deal with what pancreas-kidney 
recipients can expect from this type of transplant, 
the experience and research results obtained in sev-
eral fields of SPKT at the Hospital Santo Antonio – 
Centro Hospitalar do Porto – pancreas transplant 
programme.
  GLOBAL OUTCOMES: SURVIVAL 
AND FUNCTION
In 2006 we reported our 5-year results, describing 
candidates’ selection criteria, surgical technique, 
immunosuppressive protocol, and the main compli-
cations4. These encouraging initial data were a strong 
motivation to pursue this direction. By following the 
internationally accepted clinical guidelines, we could 
improve these data. At the 10-years mark5, our 
results continued to align with the standards of other 
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world reference centres and the international pan-
creas transplantation registry (IPTR)6. Patient, kidney 
and pancreas graft survival rates reported by our 
group were 96%, 96% and 83%, respectively, for the 
1st year and 94%, 91% and 75%, respectively, at 5 
years. The annual number of SPTK has increased, 
reaching a plateau of 12 to 15 per year. As a result 
of this increment, time on the waiting list for such a 
transplant has substantially decreased. Acute rejec-
tion incidence improved to around 16% in a more 
recent analysis of 150 patients7. Ten-year patient, 
kidney and pancreas graft survival was then 91%, 
79% and 69%, respectively. The contribution of the 
radiology department, which provides image-guided 
pancreatic biopsy, has enabled us to confirm or 
exclude pancreatic rejection more accurately in 
recent years.
A pancreas graft is considered to be functioning 
as long as it allows patients to remain free of the 
need for insulin injections. Of the first 150 SPKTs, 76% 
had a functioning pancreas graft and 87% a function-
ing renal graft7. Renal function expressed as mean 
serum creatinine and mean creatinine clearance was 
1.2mg/dl and 76 ml/min, respectively.
 COMPLICATIONS AFTER SURGERY
Higher morbidity and even mortality after SPKT 
compared to kidney transplantation alone is quite 
well known. The candidates are recognized as high-
risk patients and the procedure itself may lead to a 
higher rate of complications. In our experience, hos-
pital stay in the first admission for SPKT is approxi-
mately twice that of kidney transplantation (median 
22 days). Almost one-third of the recipients needed 
at least one surgical reintervention8 with intra-
abdominal bleeding or infection and graft thrombosis 
the majority of the causes. The readmission rate was 
also high (74.2%), mostly (57.4%) in the first year 
after the transplant8. The events occurring in the very 
early post-operative period, namely infection or graft 
thrombosis, may determine not only pancreas graft 
survival but also patient survival7. An uneventful early 
period usually indicates good mid-term results. Long-
term pancreas failure was mainly due to rejection. 
Regarding kidney graft loss, chronic rejection was the 
cause of late losses7, with one exceptional early loss 
due to thrombosis.
A multidisciplinary approach to these patients is 
mandatory and the key to the SPKT success. Our fruit-
ful collaboration with Radiology has allowed not only 
suspected pancreas rejection to be excluded or con-
firmed through biopsy, but also the diagnosis and 
sometimes the treatment for several complications 
that may occur in these patients9.
From our initial experience it seemed that peri-
toneal dialysis (PD) patients who underwent SPKT 
were more prone to developing intra-abdominal 
complications. We then conducted a study to analyse 
the differences between PD and haemodialysis (HD) 
patients and to clarify whether the two sets of 
patients had distinct outcomes10. Our study con-
firmed a higher intra-abdominal infection incidence 
and pancreas loss in PD patients. Microbial agents 
isolated from abdominal fluids after SPKT were dis-
tinct from the agents they evidenced in past perito-
nitis episodes. Additionally, PD patients tended to 
present a higher incidence of renal graft loss due to 
thrombosis, and also an increased mortality rate. We 
could not find the objective causes for this adverse 
outcome in the PD group. It is tempting to blame 
the peritoneum, previously damaged by PD and its 
complications. However, this direct relationship 
remains to be proven, as does which underlying peri-
toneal changes, or other changes, lead to those 
results. It is our aim to proceed with further studies 
in this field.
  METABOLIC OUTCOMES: 
CARDIOVASCULAR RISK FACTORS 
AND EVENTS
Cardiovascular (CV) and cerebrovascular diseases 
are the main cause of mortality in diabetic patients. 
Thus, controlling CV risk factors is crucial in reducing 
the incidence of stroke, myocardial infarction and 
peripheral artery disease. Steroids are usually part of 
the maintenance immunosuppressive protocols in solid 
organ transplantation, despite their known detrimental 
effects on hypertension, hyperlipidaemia, obesity, 
osteoporosis, and infection, among others. Steroid-free 
or steroid-limited protocols are sought, but acute rejec-
tion and graft failure are feared after steroids with-
drawal. Some years ago we confirmed the feasibility 
of steroid withdrawal, normally after the 6th month 
post-SPKT11. With a cautious patient selection – only 
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patients who could maintain tacrolimus associated with 
an anti-proliferative drug were selected – we noticed 
that steroid tapering and discontinuation can be safe, 
with no subsequent acute rejection episodes or graft 
function deterioration. Within this sample of 54 SPKT 
with more than one year of follow-up, steroid suspen-
sion was achieved in 77.8% (42 patients). We were not 
able to demonstrate statistically significant differences 
regarding the lipid profile and hypertension rate 
between those who stopped steroids and those who 
didn’t, but the limited sample may explain this lack of 
significance. Nevertheless, the results from this study, 
confirming the safety of the procedure, were important 
as they led us to implement our steroid withdrawal 
protocol.
More recently we analysed CV risk factors and CV 
events occurring in a wider sample of our SPKT 
patients, considering only those who maintained both 
grafts functioning12. Although these 103 SPKT were 
young (mean 35 years old), at the time of the trans-
plant they had a mean time of diabetes evolution of 
24 years and had been on dialysis for 30 months. The 
National Cholesterol Education Program Adult Treat-
ment Panel3 (NCEP/ATP3) criteria were followed to 
characterize metabolic syndrome (MS) in our patients. 
Only 8.7% met the criteria (≥ 3) for MS. Hypertension 
was the most frequent single criteria (in 38.5%), fol-
lowed by low HDL-c (in 19.4%) and hypertriglyceri-
demia (in 7.8%). Obesity and high fasting glucose 
levels (> 100 mg/dl) were rare. Among these patients, 
we compared the subgroup under steroids (n = 34) 
with the subgroup who stopped steroids (n = 69). 
Patients under steroids had higher triglycerides levels 
and more often tended to be hypertensive. Hyperten-
sion was associated with higher body mass index 
(BMI). BMI > 25kg/m2 was associated with higher 
total cholesterol and LDL-c levels. These results 
allowed us to confirm the association between steroid 
maintenance and worse metabolic results and sup-
port our strategy to minimize steroid exposure, when-
ever possible.
Non-fatal CV events occurred in 6.8% (n = 7) of 
patients, mostly peripheral artery disease12. We also 
looked at the other 32 patients – among the global 
135 SPKT at this time – who lost at least one graft (n 
= 26) or who died (n = 6). CV disease was the cause 
of death in two recipients. The incidence of CV events 
among those 26 alive but with one failed graft was 
substantially higher: 19.2%.
  PANCREAS-KIDNEY 
TRANSPLANTATION AND BONE 
MINERAL DISEASE
Bone mineral disease is a major concern in chronic 
renal patients and diabetes may contribute to addi-
tional bone mass loss. Several studies, mostly into 
kidney transplant recipients, have reported an initial 
bone mass worsening at least during the first 6 
months, with possible recovery thereafter13-15. A 
retrospective evaluation was made in 54 patients, 
over 4 years after SPKT16. At the time of transplanta-
tion bone mineral density (BMD) – evaluated by dual-
energy X-ray absorptiometry (DEXA) – evidenced 
osteoporosis in 28% of patients. One year after, 77.6% 
displayed improved lumbar T-score, with stable femo-
ral neck T-score. BMD gradually improved through 
the 4 years’ follow-up, more significantly at the lum-
bar level and less importantly at the femoral neck. 
At the end of the fourth year no cases of osteoporosis 
were observed, and 86.7% of patients were with-
drawn from steroids.
Subsequently, we conducted a prospective study 
evaluating BMD (by DEXA) and serum levels of bone 
mineral metabolism markers at 3 different time-
points after SPKT17. BMD and blood samples were 
obtained from 48 recipients, firstly before the end 
of the 3rd month, the other two at least 2 years after 
the transplant and one year apart. At the first evalu-
ation 35.4% were categorized as having lumbar 
osteoporosis and 39.6% as having femoral neck 
osteoporosis. Osteoporotic patients (lumbar/femo-
ral) presented higher alkaline phosphatase levels. 
Patients with lumbar osteoporosis had significantly 
lower BMI. BMD significantly improved in subse-
quent evaluations, in both sites. Parathyroid hor-
mone progressively decreased. At the end of follow-
up 81.2% had been withdrawn from steroids. 
Multivariate analysis identified BMI increase as 
positively associated with BMD improvement and 
high values of alkaline phosphatase as increasing 
the risk of inferior BMD scores. The frequency of 
patients with osteoporosis at the last follow-up 
decreased to 4.2% at lumbar spine and 8.3% at femo-
ral neck. Patients who remained osteoporotic pre-
sented the lowest BMI. This study provided addi-
tional evidence of bone density gain after SPKT and 
identified two factors, one with negative and another 
with positive correlation with BMD: alkaline phos-
phatase and BMI, respectively.
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  AUTOIMMUNITY RELAPSE AFTER 
SPKT
At the time of DM1 diagnosis, most patients pre-
sent circulating autoantibodies against pancreatic 
beta-cell antigens; additionally, an inflammatory 
infiltrate surrounding these cells has been docu-
mented. The autoimmune nature of the disease can 
be proved in nearly 95% of DM1 cases. After the 
onset and over the years, in the majority of patients 
these anti-islet antibodies tend to decrease and 
eventually to disappear, although in some patients 
they remain detectable.
When these patients are transplanted with a 
healthy pancreas, they express newly these islet 
antigens, corresponding to the new beta-cells. 
Immunosuppression applied to control alloimmun-
ity in pancreas transplant recipients would be 
expected to also control autoimmune response. 
However, the first case of autoimmune diabetes 
recurrence after pancreas transplantation was 
described in 198418. Thereafter several cases have 
been documented, despite maintained immunosup-
pression and with alloimmunity apparently con-
trolled19. The study of the causes leading to graft 
dysfunction or failure excluded graft rejection and 
confirmed a lymphocytic infiltrate selectively target-
ing Langerhans islets beta-cells, sparing the other 
cell types and the pancreatic exocrine tissue20. In 
such cases, it is usual to observe a recurrence or 
an increase in pancreatic autoantibodies titles also. 
Some authors estimate that autoimmune diabetes 
recurrence may be responsible for half of the immu-
nological pancreas graft losses, about 5%21. It is 
likely that this entity has been underdiagnosed and 
underevaluated.
In an initial prospective analysis of 65 SPKT with 
both grafts functioning performed in our unit, we 
noticed that one-third had positive pancreatic 
autoantibodies; some de novo, some with rising 
titres22. We could not correlate this positivity with 
acute rejection, HLA-mismatches, steroid withdraw-
al, or immunosuppressive drugs levels. Within the 
subgroup with positive pancreatic antibodies we 
found patients with the worst glycaemic profile, 
although this was not statistically significant. Our 
second study, into prospective determination of 
pancreatic autoantibodies in 135 SPKT23, confirmed 
that these autoantibodies may remain positive or 
negative, or recur after transplantation. With such 
a larger sample we were able to demonstrate a nega-
tive impact of this positivity on pancreas graft func-
tion: higher fasting glucose levels, higher glycated 
haemoglobin (HbA1c) and lower C-peptide levels 
were registered in the subgroup with positive pan-
creatic autoantibodies. The odds of having these 
autoantibodies positive was 5.2 times higher among 
those with HbA1c > 5.6%, and 35% lower within 
those with higher C-peptide levels. Risk factors asso-
ciated with the pancreatic autoimmune relapse did 
not emerge from this study, which encourages us 
to continue our search on this field. In a review arti-
cle, we analysed the most interesting papers pub-
lished on this theme24. Recent studies, namely 
regarding cellular immunity, have shown the role of 
the immune memory response and also the inability 
of immunosuppressive drugs currently used in organ 
transplantation to prevent this autoimmune process. 
Based on obtained data, several anti-T cell and anti-B 
cell therapies have been tried. To date, these 
attempts failed to prove sustained effectiveness in 
the treatment of this disease25.
 ALLOIMMUNITY IN SPKT
Acute rejection incidence has decreased in several 
solid organ transplants and also in SPKT. The role of 
de novo donor-specific anti-HLA antibodies (DSA) 
emerging after kidney transplantation is quite well 
documented. However, there are scarce data about 
its relevance in SPKT26,27. Within a group of 136 SPKT 
we detected de novo DSA in 13.2%, after a median 
period of 3.3 years (from 0.4 to 8.7 years) post-trans-
plantation28. Recipient younger age, pre-transplant 
(non donor-specific) HLA sensitization, mismatches 
in HLA-DR, and acute rejection were risk factors for 
DSA appearance. Acute rejection episodes of any 
graft, proven by kidney or pancreas biopsies, in par-
ticular vascular rejections, correlated with DSA emer-
gence. Our data showed that DSA presence predicted 
the loss of each graft, independently, and loss of both 
grafts. The number of DSA detected, DSA against HLA 
class I+II, and their intensity, increased proportionally 
to the number of failed grafts. The median time 
between DSA appearance and graft loss was 10 
months. Multivariate analysis revealed that DSA and 
acute rejection were independent predictors of graft 
loss: DSA-positive patients, but without evidence of 
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acute rejection, evolved more to graft failure than 
the DSA-negative. From these data we observed that 
de novo DSA screening, and the analysis of their char-
acteristics, is helpful to identify patients at risk of 
graft failure also in SPKT. Nevertheless, the efficacy 
of the available therapeutic interventions is still unsat-
isfactory. At its date of publication, this was the study 
with the longest follow-up into DSA evaluation in SKPT, 
and the first reporting such results based also on 
pancreas biopsies.
  ADVANCED-GLYCATION 
ENDPRODUCTS (AGE) EVOLUTION 
AFTER SPKT
Increased AGE accumulation in diabetic patients 
is one of the most important pathways of microvas-
cular injury29. AGE were also correlated with diabetic 
macrovascular disease30. After successful SPKT, 
patients restore normoglycaemia and renal function, 
two mechanisms that may decrease AGE production 
and deposition. However, this is an issue scarcely 
studied.
We conducted a prospective study to evaluate 
plasmatic and skin AGE evolution after SPKT31. 
Blood samples were collected on day 0, then at 3, 
6 and 12 months after the transplant, in 20 patients. 
Carboxymethyllisine (CML), which is a well-known 
specific AGE, global AGE, and advanced oxidation 
protein products (AOPP) were analysed in plasma. 
Skin biopsies were collected on day 0 (during the 
surgery) and 12 months after SPKT. Immunochem-
istry with anti-AGE antibody was used to evaluate 
skin AGE deposits. There was an initial rise of CML, 
AGE and AOPP from 0 to 3 months, possibly associ-
ated to more intense inflammatory/infectious 
insults during this period. Thereafter, the markers 
progressively decreased. This decrease was statisti-
cally significant for CML and nearly significant for 
AOPP. Among several variables analysed, possibly 
interfering with AGE variation, only time on dialysis 
presented a nearly significant positive correlation 
with CML values.
The most common finding in skin biopsies regard-
ing AGE immunostaining – comparing day 0 with 1 
year post-transplant samples, for each patient – was 
a change from a cytoplasmic diffuse pattern to a 
peripheral pattern, saving the central cytoplasmic 
area31. A decrease on the AGE immunoreaction inten-
sity was also observed in one-half of patients. Despite 
the short follow-up, we are able to report an AGE 
reduction in this early period (1 year after SPKT), at 
tissue and at plasma level. A subsequent study is 
planned to consubstantiate these data, in a larger 
sample with extended follow-up.
  CHANGES IN QUALITY OF LIFE 
(QOL) AFTER SPKT
Assessment of QoL in organ transplant pro-
grammes is often forgotten. If there is any transplant 
which can change QoL, it should be the pancreas-
kidney transplant, which treats 2 severe diseases, 
diabetes and end-stage renal disease. Although the 
complex initial period after SPKT may hamper or 
delay the QoL gain, when patients overcome this 
period, the improvement tends to be very significant 
– more than that achieved with an isolated kidney 
transplant32,33. We have additionally addressed this 
issue in our SPKT population34. The QoL was 
assessed through two surveys: a generic one, the 
SF-36, and a more specific one, the GIQLI (gastro-
intestinal quality of life index), to evaluate gastro-
intestinal complaints, which are so frequently disa-
bling for DM1 patients. Comparing pre-transplant 
status with last follow-up status, the results showed 
an impressive QoL gain at all levels: physical, social 
and psychological. The presence of two functioning 
grafts was predictor of greater QoL improvement. 
The health perception score rose from 40% at base-
line to 80% after SPKT. Further, patients experienced 
a significant improvement in most gastrointestinal 
symptoms. Moreover, the rate of patients working 
or able to work increased considerably after the 
transplant.
Our experience, described above, leaves us with 
the firm conviction that SPKT is the best possible 
treatment for DM1 patients with end-stage renal dis-
ease, despite the initial morbidity and possible com-
plications associated with the procedure. If these 
patients are able to be transplanted, we strongly 
recommend referring them to a pancreas-kidney 
transplant programme.
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